Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Mar 26, 2024 08:01AM
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium Dec 1, 2023 08:01AM
Intensity Therapeutics (INTS) Presents Positive INT230-6 Data Nov 2, 2023 07:03AM
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023 Nov 2, 2023 07:01AM
Intensity Therapeutics (INTS) Granted Orphan Drug Designation for the three key ingredients in INT230-6 Sep 7, 2023 08:02AM


Sep 7, 2023 08:01AM Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Sep 5, 2023 08:01AM Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 07:01AM Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Aug 7, 2023 07:01AM Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Jul 31, 2023 04:05PM Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
Jul 10, 2023 08:00AM Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
Jul 5, 2023 04:15PM Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 30, 2023 05:06AM Intensity Therapeutics (INTS) Prices Upsized 3.9M Share IPO at $5/sh
Jun 29, 2023 08:00PM Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 6, 2023 07:35AM Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
Jun 3, 2023 08:00AM Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
Dec 8, 2022 07:01AM Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS
Nov 18, 2022 07:01AM Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic
Nov 11, 2022 07:01AM Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
Nov 10, 2022 07:01AM Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers